Evidence map›Paper›PMID 27677741›Full record

ArticleLeukemia2017

Pharmacogenomics and chemical library screens reveal a novel SCF

E Malek, M A Y Abdel-Malek, S Jagannathan, N Vad, R Karns, A G Jegga, A Broyl, M van Duin, P Sonneveld, F Cottini and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 55 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. The cross talk of ubiquitination and chemotherapy tolerance in colorectal cancer.Journal of cancer research and clinical oncology · 2024
    Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 3 countries.

E MalekDepartment of Hematology and Oncology, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
M A Y Abdel-MalekThe Vontz Center for Molecular Studies, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
S JagannathanThe Vontz Center for Molecular Studies, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
N VadThe Vontz Center for Molecular Studies, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
R KarnsDepartment of Biomedical Informatics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
A G JeggaDepartment of Biomedical Informatics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
A BroylDepartment of Hematology, Erasmus Medical Center and University, Rotterdam, The Netherlands.
M van DuinDepartment of Hematology, Erasmus Medical Center and University, Rotterdam, The Netherlands.
P SonneveldDepartment of Hematology, Erasmus Medical Center and University, Rotterdam, The Netherlands.
F CottiniDepartment of Medicine, Harvard Medical School, Boston, MA, USA.
K C AndersonDepartment of Medicine, Harvard Medical School, Boston, MA, USA.
J J DriscollThe Vontz Center for Molecular Studies, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Erasmus MC · NLUniversity of Cincinnati Medical Center · USCincinnati Children's Hospital Medical Center · USHarvard University · USAssiut University · EGCase Western Reserve University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While clinical benefit of the proteasome inhibitor (PI) bortezomib (BTZ) for multiple myeloma (MM) patients remains unchallenged, dose-limiting toxicities and drug resistance limit the long-term utility. The E3 ubiquitin ligase Skp1-Cullin-1-Skp2 (SCF

Indexed as

PharmacogeneticsSmall Molecule LibrariesAdaptor Proteins, Signal TransducingAnimalsAntineoplastic AgentsCell Line, TumorCell SurvivalCullin ProteinsDisease Models, AnimalDrug DiscoveryDrug Resistance, NeoplasmDrug SynergismFemaleGene ExpressionGene Knockdown TechniquesHumansAdaptor Proteins, Signal TransducingAntineoplastic AgentsCOMMD1 protein, humanCullin 1Cullin ProteinsProteasome InhibitorsSmall Molecule LibrariesS-Phase Kinase-Associated Proteins

Identifiers

PMID27677741
PMCPMC5339431
OpenAlexW2524526446

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.